Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Tmunity Therapeutics

    - PMLiVE

    Gilead’s Yescarta shows benefits for patients with large B-cell lymphoma

    This is the most common type of non-Hodgkin lymphoma worldwide

    - PMLiVE

    Gilead reports Trodelvy breast cancer trial missed primary survival endpoint

    The drug treatment is being evaluated in several ongoing phase 3 trials

    - PMLiVE

    BMS acquires Orbital Therapeutics in $1.5bn deal

    The deal includes several next-gen cell therapy candidates for autoimmune diseases

    - PMLiVE

    Gilead shares promising phase 3 results for Trodelvy plus Keytruda in aggressive breast cancer

    Triple-negative breast cancer accounts for approximately 15% of all cases of the disease

    - PMLiVE

    Gilead’s seladelpar recommended by CHMP to treat primary biliary cholangitis

    The rare liver disease affects approximately 15 per 100,000 people in Europe

    - PMLiVE

    Roche expands cell therapy capabilities with $1.5bn Poseida acquisition

    The deal includes a BCMA-targeting allogeneic CAR-T therapy candidate for multiple myeloma

    - PMLiVE

    AstraZeneca announces $3.5bn US investment to boost research and manufacturing

    The commitment is part of the company’s ambition to achieve $80bn in total revenue by 2030

    - PMLiVE

    Gilead’s Livdelzi receives FDA accelerated approval to treat primary biliary cholangitis

    The company gained access to the drug through its $4.3bn acquisition of CymaBay in March

    - PMLiVE

    Kite and Arcellx expand cell therapy partnership in deal worth over $285m

    The companies' existing CART-ddBCMA collaboration now covers lymphomas

    - PMLiVE

    Kite and Epic Bio announce cancer cell therapy collaboration agreement

    The partnership centres around Epic Bio’s proprietary gene regulation platform

    - PMLiVE

    Novo Nordisk Foundation commits €127m for new cell therapy facility

    The new facility will help accelerate treatments for people living with chronic diseases

    - PMLiVE

    Astellas invests $50m to support advancement of Poseida’s cancer cell therapy

    The company will gain the first refusal to one of Poseida’s clinical stage programmes

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links